Litcius/Paper detail

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

Thomas Powles, Zoe J. Assaf, Nicole N. Davarpanah, Romain Banchereau, Bernadett Szabados, Kobe Yuen, Petros Grivas, Maha Hussain, Stéphane Oudard, Jürgen E. Gschwend, Peter Albers, Daniel Castellano, Hiroyuki Nishiyama, Siamak Daneshmand, Shruti Sharma, Bernhard Zimmermann, Himanshu Sethi, Alexey Aleshin, Maurizio Perdicchio, Jingbin Zhang, David S. Shames, Viraj Degaonkar, Xiaodong Shen, Corey Carter, Carlos Bais, Joaquim Bellmunt, Sanjeev Mariathasan

2021Nature604 citationsDOI

Topics & Concepts

Hazard ratioMedicineAtezolizumabInternal medicineConfidence intervalOncologyPopulationClinical endpointAdjuvantBladder cancerAdjuvant therapyBiomarkerImmunotherapyCancerRandomized controlled trialNivolumabBiologyEnvironmental healthBiochemistryBladder and Urothelial Cancer TreatmentsCancer Genomics and DiagnosticsEpigenetics and DNA Methylation
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma | Litcius